Feasibility of neoadjuvant chemotherapy with modified FOLFOX6 (combination chemotherapy of infusional 5-FU/l-Leucovorin and intermittent oxaliplati...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter C. Kosugi
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors C. Kosugi, K. Koda, K. Tanaka, Y. Miyazawa, K. Shuto, K. Matsuo, M. Mori, A. Hirano, S. Endo, Y. Hiroshima, T. Sazuka, H. Yanagibashi, Y. Kikuchi
  • Department of Surgery, Teikyo University Chiba Medical Center, Ichihara, Japan, /

Abstract

Preoperative chemoradiotherapy with total mesorectal excision (TME) is the recommended standard therapy for patients with locally advanced rectal cancer. Sauer et al (N Engl J Med 2004) reported a randomized study that showed that preoperative chemoradiotherapy (CRT) improved local control and was associated with reduced toxicity compared with postoperative chemoradiotherapy. However, some reports have shown increased frequency of bowel movements, incontinence, urgency, and emptying difficulties in irradiated patients. Therefore, it is necessary for aggressive preoperative chemotherapy to obtain local control and to avoid a postoperative defecation function disorder. In the present pilot study, the safety and utility of preoperative chemotherapy with modified (m) OPTIMOX1 plus bevacizumab were evaluated in patients with advanced rectal cancer with factors contraindicative of curative surgery.